Nobivac Tricat Trio, Lyophilisate and Solvent for Suspension for Injection for Cats

Երկիր: Միացյալ Թագավորություն

Լեզու: անգլերեն

Աղբյուրը: VMD (Veterinary Medicines Directorate)

Ակտիվ բաղադրիչ:

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Հասանելի է:

MSD Animal Health UK Limited

ATC կոդը:

QI06AD04

INN (Միջազգային անվանումը):

Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus

Դեղագործական ձեւ:

Lyophilisate and solvent for suspension for injection

Ռեկվիզորի տեսակը:

POM-V - Prescription Only Medicine – Veterinarian

Թերապեւտիկ խումբ:

Cats

Թերապեւտիկ տարածք:

Live Viral Vaccine

Լիազորման կարգավիճակը:

Authorized

Հաստատման ամսաթիվը:

2007-05-01

Ապրանքի հատկությունները

Revised: February 2023
AN: 00709/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Tricat Trio, lyophilisate and solvent for suspension for
injection for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (1 ml) of reconstituted vaccine contains:
ACTIVE SUBSTANCES:
Live attenuated feline calicivirus, strain F9:

10
4.6
PFU
1
;
Live attenuated feline rhinotracheitis virus, strain G2620A:

10
5.2
PFU
1
;
Live attenuated feline panleucopenia virus, strain MW-1:

10
4.3
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
:
Cell Culture Infectious Dose 50%
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
Lyophilisate: off-white pellet.
Solvent: clear colourless solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of cats:
- to reduce the clinical signs caused by infection with feline
calicivirus (FCV) and
rhinotracheitis virus (FVR),
- to prevent the clinical signs, leucopenia and virus excretion caused
by infection with
feline panleucopenia virus (FPLV).
Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks.
Duration of immunity for FCV and FVR: 1 year, for FPLV: 3 years.
4.3
CONTRAINDICATIONS
See section 4.7
Revised: February 2023
AN: 00709/2022
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
Maternal antibodies, which may persist up to the age of 9-12 weeks,
can have a
negative influence on the efficacy of vaccination. In the presence of
maternal
antibodies, vaccination may not completely prevent the clinical signs,
leucopenia and
virus excretion following an FPLV infection. In such cases where a
relatively high level
of maternally derived antibodies is expected, the vaccination schedule
should be
planned accordingly.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals:
Not applicable.
Special precautions to be